The stock has fallen from a peak back in April.

The stock has climbed in the double-digits in recent years.

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...

Prediction: Vertex will be much larger by the end of the decade.

Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals ...

Dec 6 (Reuters) - Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY ® (exagamglogene autotemcel) in people ages 5 years and ...

If you have ever wondered whether Vertex Pharmaceuticals is a bargain right now, you are not alone. Let's break down whether ...

Building on years of trusted partnership, Vertex and CPA.com are bringing advanced artificial intelligence and automation to the forefront of sales tax compliance. This enhanced solution enables ...

Tax solutions provider Vertex announced its acquisition of Germany-based e-invoicing software specialist Ecosio. The terms of the acquisition include an upfront cash payment of $69 million as well as ...

Vertex Founder and CEO Wayne Smith selected Cooper to harness the company’s momentum and carefully articulate the Vertex ...